Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey by Del Barrio-Tofiño, Ester et al.
Association between Pseudomonas aeruginosa O-antigen serotypes,
resistance profiles and high-risk clones: results from a Spanish
nationwide survey
Ester del Barrio-Tofi~no1, Irina Sánchez-Diener1, Laura Zamorano1, Sara Cortes-Lara1, Carla López-Causapé1,
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Objectives: To evaluate the correlation of O-antigen serotypes with resistance profiles and high-risk clones in a
Spanish nationwide survey.
Methods: Up to 30 consecutive healthcare-associated Pseudomonas aeruginosa isolates were collected during
October 2017 from each of 51 hospitals (covering all Spanish regions) with a total of 1445 isolates studied. MICs
of 13 antipseudomonal agents and MDR/XDR profiles had been previously determined, as well as whole-genome
sequences of 185 representative XDR isolates. O-antigen serotypes (O1–O16) were determined by agglutination
using serotype-specific antisera (BioRad). The Pseudomonas aeruginosa serotyper (PAst) program was used for
in silico serotyping.
Results: The most frequent serotypes were O6 (17.8%), O1 (15.4%) and O11 (13.3%). In contrast, the most fre-
quent serotype among XDR isolates (17.3%) was O4 (34.1%), distantly followed by O11 (15.9%). Within sero-
types, XDR phenotypes were more frequent for O12 (60.0%) and O4 (57.3%). The most frequent clone among
the XDR isolates was ST175 (40.9%), followed by CC235 (10.7%), ST308 (5.2%) and CC111 (3.6%). Up to 81.6% of
XDR ST175 isolates typed O4, whereas 18.4% were non-typeable. O4 genotype was detected in all sequenced
(n=55) ST175 isolates. On the other hand, CC235 and ST308 were associated with O11, whereas CC111 was
linked to serotype O12.
Conclusions: O4 serotype is linked to the MDR/XDR profile of widespread ST175 (typically only susceptible to co-
listin, amikacin and the novel combinations ceftolozane/tazobactam and ceftazidime/avibactam) and therefore,
after local validation, its detection in the microbiology laboratory might be useful for guiding semi-empirical anti-
pseudomonal therapies and infection control measures in Spanish hospitals.
Introduction
The growing prevalence of nosocomial infections produced by
MDR and particularly XDR Pseudomonas aeruginosa strains is asso-
ciated with significantly increased morbidity and mortality.1 This
increasing threat results from the extraordinary capacity of
P. aeruginosa for developing resistance to nearly all available anti-
biotics by the selection of mutations in chromosomal genes and
from the growing prevalence of transferable resistance determi-
nants, particularly those encoding carbapenemases or ESBLs.2 The
dissemination of MDR/XDR global strains, the high-risk clones, in
multiple hospitals worldwide adds further concern.3 Since high-risk
clones are associated with defined MDR/XDR profiles, diagnostic
approaches to their early detection would be useful for guiding
antipseudomonal therapies. The most widely accepted gold-
standard technique for the definition of such epidemic clones is
MLST.3,4 Moreover, WGS provides further relevant information for
understanding the dissemination and the resistome of MDR/XDR
P. aeruginosa high-risk clones.5–7 However, MLST and WGS, and
other classical molecular typing techniques such as PFGE, are still
time consuming and thus not practical for implementation in the
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current diagnostic microbiology routine for guiding antipseudomo-
nal therapies. On the other hand, O-antigen serotyping is a rapid,
simple and cheap procedure that, despite not being as discrimin-
atory as those mentioned above, might be useful for the presump-
tive detection of at least some MDR/XDR high-risk clones.3,8,9
Moreover, a program [Pseudomonas aeruginosa serotyper (PAst)]
for in silico serotyping of P. aeruginosa isolates from WGS data has
recently been developed.10 However, large-scale surveys of O-
antigen serotypes are very scarce and/or old, and none has been
performed so far in Spain. Thus, the objective of this work was to
determine the association between P. aeruginosa O-antigen sero-
types, resistance profiles and high-risk clones, taking advantage of
a recent large-scale Spanish nationwide survey of P. aeruginosa
infections.11
Material and methods
P. aeruginosa strain collection
The collection studied included up to 30 consecutive healthcare-associated
non-duplicated (one per patient) P. aeruginosa clinical isolates collected
during October 2017 from each of the 51 participating hospitals, covering
all 17 Spanish regions.11 A total of 1445 isolates were studied. The distribu-
tion of sample types was as follows: respiratory (32.8%), urine (23.7%), soft
tissue and osteoarticular (23.1%), blood culture (5.7%) and others (14.9%).
MICs of ticarcillin, piperacillin/tazobactam, ceftazidime, cefepime, ceftolo-
zane/tazobactam (4 mg/L), ceftazidime/avibactam (4 mg/L), aztreonam,
imipenem, meropenem, ciprofloxacin, tobramycin, amikacin and colistin
had been determined by broth microdilution according to EUCAST guide-
lines (www.eucast.org). EUCAST v 8.1 clinical breakpoints were used for
interpretation. Up to 252 (17.4%) of the isolates met the XDR criteria.12 In
the previous study,11 clonal relatedness among XDR isolates had been ini-
tially evaluated by PFGE and one representative XDR isolate from each
unique macrorestriction pattern and hospital (n=185) was further ana-
lysed through WGS, including MLST and resistome analysis.
O-antigen serotyping
O-antigen serotypes (O1–O16) were determined in the 1445 isolates by ag-
glutination using commercially available serotype-specific antisera (BioRad
ref. 58901–58916, from O1 to O16). The PAst program10 (https://cge.cbs.
dtu.dk/services/PAst-1.0/) was used for in silico serotyping of the 185 XDR
isolates sequenced. The v2 test was used for the analysis of the prevalence
of serotypes in different subgroups. A P value <0.05 was considered statis-
tically significant.
Results
As shown in Table 1, the most frequent serotypes among the 1445
isolates tested were O6 (17.8%), O1 (15.4%) and O11 (13.3%). Up
to 14.5% of the isolates were non-typeable (no agglutination or
polyagglutination with the 16 antigens tested). Significant differ-
ences in serotype distribution according to the sample type were
not detected (not shown). However, the distribution of serotypes
was very different among XDR isolates. Interestingly, the most fre-
quent serotype among XDR isolates (17.4%) was by far O4,
detected in 34.1% of the isolates (versus 10.4% of all isolates
P<0.0001), distantly followed by O11 (15.9%) (Table 1). Although
globally not frequent, O12 serotype was also significantly associ-
ated with the XDR phenotype (4.8% versus 1.4%, P<0.0001).
Finally, non-typeability was also significantly associated with XDR
isolates (24.2% versus 15.5%, P=0.0007).
The distribution of non-MDR/MDR/XDR phenotypes among the
main serotypes is shown in Figure S1 (available as Supplementary
data at JAC Online). As shown, the serotype more strongly associ-
ated with XDR phenotypes was O12 (60.0% of XDR isolates), closely
followed by O4 (57.3%). The next serotypes were O11 and O16,
with only 20.7% and 15% of XDR isolates, respectively. Moreover,
all other serotypes yielded XDR rates <10%. On the other hand, the
prevalence of XDR phenotype among non-typeable isolates was
29.2%.
In silico O-antigen serotyping was analysed in the 185
sequenced XDR isolates. Table S1 shows the in vitro and in silico O-
antigen serotypes for these strains, together with their STs, suscep-
tibility profiles and resistomes. Agreement between in vitro and in
silico serotyping was documented in 125 (67.6%) of the isolates.
Lack of coincidence was mostly caused by isolates non-typeable
by conventional serotyping (30.8%) rather than by serotype dis-
crepancies (1.6%). Table 2 shows the comparative analysis of
in vitro and in silico serotyping in the most frequent XDR clones
detected in the study (ST175, CC235, CC111 and ST308). As can be
observed, ST175 was clearly associated with O4 serotype; 81.6%
of all ST175 isolates analysed (n=103) were O4, and the remaining
18.4% were non-typeable, by in vitro serotyping, whereas all 55
sequenced ST175 isolates showed an O4 in silico serotype.
Likewise, CC111 isolates were associated with O12 serotype and
CC235 and ST308 with O11. However, some exceptions were docu-
mented, such as one ST111 showing an O4 in silico serotype (non-
typeable by in vitro serotyping) and a few CC235 isolates showing
an O1 serotype by in vitro serotyping. Association of serotypes with
susceptibility profiles and resistance mechanisms was not evi-
denced beyond the link with STs, although the percentage of non-
typeable strains was particularly high (40%) among those produc-
ing carbapenemases or ESBLs (Table S1).
Table 1. Distribution of O-antigen serotypes among the complete collec-
tion of P. aeruginosa isolates as well as those showing an XDR phenotype
Serotype
Total isolates, n (%)
(n=1445)
XDR isolates, n (%)
(n=252)a
O1 222 (15.4) 13 (5.2)*
O2 58 (4.0) 4 (1.6)*
O3 100 (6.9) 8 (3.2)*
O4 150 (10.4) 86 (34.1)**
O5 75 (5.2) 1 (0.4)*
O6 257 (17.8) 18 (7.1)*
O7 39 (2.7) 0 (0.0)*
O8 17 (1.2) 0 (0.0)
O9 20 (1.4) 1 (0.4)
O10 49 (3.4) 3 (1.2)*
O11 193 (13.3) 40 (15.9)
O12 20 (1.4) 12 (4.8)**
O13 3 (0.2) 0 (0.0)
O14 6 (0.4) 0 (0.0)
O15 7 (0.5) 2 (0.8)
O16 20 (1.4) 3 (1.2)
Non-typeable 209 (14.5) 61 (24.2)**
aStatistically significant (v2, P<0.05) lower (*) or higher (**) prevalence of
each serotype among XDR isolates compared with non-XDR isolates.
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Discussion
To our knowledge, this is the first large-scale (1445 isolates) na-
tionwide (51 hospitals covering all Spanish regions) survey on the
distribution of P. aeruginosa O-antigen serotypes among
healthcare-associated clinical isolates ever performed worldwide.
Using commercially available antisera (BioRad) covering 16 (O1–
O16) of the 20 O-specific antigens defined by the International
Antigenic Typing Scheme (IATS),9 14.5% of the isolates were non-
typeable and thus represented a relatively minor issue for the ap-
plication of this typing scheme. This proportion of non-typeable
isolates was indeed lower than that documented in another previ-
ous large study (35%),8 likely owing to the overrepresentation of
cystic fibrosis (CF) isolates, which are mostly non-typeable owing
to the loss of the O-antigen as part of the adaptive process for
long-term persistence in chronic infections. Although CF isolates
were not excluded in our study, they represented <1% of the con-
secutive isolates included.
Serotypes O6, O1 and O11 were the most frequent among P.
aeruginosa clinical isolates from Spanish hospitals in our study.
Although a comparison with other previous surveys is not straight-
forward owing to the small number of isolates included or strain
selection bias (such as MDR or CF), these three serotypes appear to
be those most frequent globally.8,13,14
Beyond a typing procedure with low discriminatory capacity in
outbreak characterization, O-antigen serotypes have been used as
a (likely indirect) marker of strain virulence or clinical out-
come.13,15,16 However, the likely most prominent feature is the as-
sociation of certain serotypes with MDR/XDR profiles. While O11
and O12 have been extensively linked to MDR/XDR strains world-
wide,3 our work shows that the most frequent serotype among
Spanish XDR isolates is by far O4, linked to the widespread ST175
high-risk clone. Serotype O12 was also strongly linked to XDR pro-
files in our study, but the overall prevalence of this serotype, linked
to ST111, was very low. On the other hand, despite the fact that our
results showed that O11 was frequent among P. aeruginosa isolates
from Spanish hospitals, it was not so strongly linked to XDR profiles,
even if documented in ST235 and ST308 high-risk clones.
Overall, a high degree of concordance between in vitro and in
silico serotyping was documented, but, as previously described,10
the latter approach enabled nearly 100% typeability. Moreover, in
silico serotyping detected one O4 ST111 isolate (non-typeable
in vitro), whereas all other sequenced isolates from this clone
were, as expected, O12. Interestingly, a recent study suggested
that in fact ST111 was originally O4 and that it became an epidem-
ic MDR clone following acquisition of O12 determinants and a quin-
olone resistance mutation in gyrA [C248T (T83I)].17 Indeed, the
resistome analysis performed indicated that the single O4 ST111
isolate was the only isolate studied from this clone not showing
the GyrA T83I mutation (Table S1). Therefore, this isolate, despite
showing an XDR profile, appears to have diverged prior to the
emergence of the O12 ST111 epidemic strain. In relation to the po-
tential association between O-antigen serotypes and GyrA muta-
tions, it is noteworthy that the widespread O4 ST175 clone
invariably shows a combination of two GyrA mutations (T83I and
D87N) (Table S1); the role of this association in the epidemic dis-
semination of this clone needs to be further explored.
In summary, this large-scale nationwide survey on the distribu-
tion of P. aeruginosa O-antigen serotypes among healthcare-
associated clinical isolates revealed that O4 serotype is very
strongly linked to the MDR/XDR profile of widespread ST175 (typic-
ally only susceptible to colistin, amikacin and the novel combina-
tions ceftolozane/tazobactam and ceftazidime/avibactam) and
therefore its detection in the microbiology laboratory might be
useful for guiding semi-empirical antipseudomonal therapies and
infection control measures in Spanish hospitals. However, its im-
plementation needs to be adapted to the local epidemiological
data (circulating high-risk clones and associated resistance pro-
files). Likewise, the occurrence of false-positive results should be
considered (>30% of O4 isolates were non-MDR) and false-nega-
tive results (20% of ST175 isolates were classified as non-
typeable).Thus, it might be useful to combine O-antigen serotyping
with other simple procedures, such as MALDI-TOF biomarker peak
analysis,18 for the rapid detection of high-risk clones in the clinical
microbiology laboratory.
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